{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-24-000060","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.838999+00:00","generated_at":"2026-06-03T02:22:55.693061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28","bullets":["Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).","GAAP net loss $0.28 per share vs $0.14 loss in Q1 2023; operating loss $10.9M (includes $4M prior-year legal settlement gain).","Adjusted EBITDA $2.8M vs $1.9M a year ago; adjusted loss per share $0.25 vs $0.23.","Gross margin 74.7%, up 21 bps YoY on favorable product/geographic mix.","CEO cites strong start with growth across all franchises; new product launches and clinical research ahead."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-24-000060","json":"https://secwatch.observer/filing/0001323885-24-000060.json","markdown":"https://secwatch.observer/filing/0001323885-24-000060.md","text":"https://secwatch.observer/filing/0001323885-24-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000060/0001323885-24-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000060/atrc-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:22:55.693061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}